Literature DB >> 21938013

Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.

Leslie van der Fits1, Jacoba J Out-Luiting, Marieke A van Leeuwen, Janneke N Samsom, Rein Willemze, Cornelis P Tensen, Maarten H Vermeer.   

Abstract

Sézary syndrome (SS) is a cutaneous T-cell lymphoma (CTCL) with malignant CD4+ T cells (SS cells) in skin, lymph nodes, and blood. Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in SS cells, whereas this activation is lost upon in vitro culturing, indicating that STAT3 activation observed in vivo is the result of activating factors in the micromilieu of the malignant cells. We investigated which factors are involved in STAT3 activation in SS, focusing on cytokines of the common γ-chain family because of their crucial role in T-cell activation. Furthermore, downstream effects of STAT3 signaling in SS cells were assayed. In SS cells, STAT3 was strongly activated by IL-21, and increased expression of IL-21 and its receptor chains was observed in peripheral blood SS cells. IL-21 and IL-21R protein expression was detectable on neoplastic cells in SS skin biopsies. Using short-term culturing experiments, we demonstrate that IL-21 itself and the α-chain of the IL-2 receptor are STAT3 target genes in SS cells, thereby rendering cells more sensitive to stimulation with the T-cell proliferation and activating cytokine IL-2. Combined, our data point toward a pivotal role for an autocrine positive feedback loop involving IL-21 and consequent persistent STAT3 activation in the pathogenesis of SS, thereby indicating IL-21 and IL-21R as new therapeutical targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21938013     DOI: 10.1038/jid.2011.293

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  13 in total

1.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

2.  miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway.

Authors:  Liang Xia; Linlin Wu; Hailong Xia; Jing Bao; Qingsheng Li; Xiaowen Chen; Ruixiang Xia
Journal:  Cell Cycle       Date:  2019-06-18       Impact factor: 4.534

3.  Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.

Authors:  Ivan V Litvinov; Brendan Cordeiro; Simon Fredholm; Niels Ødum; Hanieh Zargham; Yuanshen Huang; Youwen Zhou; Kevin Pehr; Thomas S Kupper; Anders Woetmann; Denis Sasseville
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

4.  Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.

Authors:  Elena Netchiporouk; Ivan V Litvinov; Linda Moreau; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

5.  Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma.

Authors:  Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Ivan V Litvinov; Simon Fredholm; David L Petersen; Claudia Nastasi; Robert Gniadecki; Nigel P Mongan; Denis Sasseville; Mariusz A Wasik; Charlotte M Bonefeld; Carsten Geisler; Anders Woetmann; Lars Iversen; Mogens Kilian; Sergei B Koralov; Niels Odum
Journal:  Blood       Date:  2016-01-05       Impact factor: 22.113

Review 6.  A three-signal model of T-cell lymphoma pathogenesis.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-17       Impact factor: 10.047

7.  CD4 T-cell cytokines synergize to induce proliferation of malignant and nonmalignant innate intraepithelial lymphocytes.

Authors:  Yvonne M C Kooy-Winkelaar; Dagmar Bouwer; George M C Janssen; Allan Thompson; Martijn H Brugman; Frederike Schmitz; Arnoud H de Ru; Tom van Gils; Gerd Bouma; Jon J van Rood; Peter A van Veelen; M Luisa Mearin; Chris J Mulder; Frits Koning; Jeroen van Bergen
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-03       Impact factor: 11.205

8.  New perspectives on the ligands and function of the killer cell immunoglobulin-like receptor KIR3DL2 in health and disease.

Authors:  Jacqueline Shaw; Simon Kollnberger
Journal:  Front Immunol       Date:  2012-11-16       Impact factor: 7.561

9.  EPHA4 is overexpressed but not functionally active in Sézary syndrome.

Authors:  Liesbeth Hameetman; Leslie van der Fits; Willem H Zoutman; Jacoba J Out-Luiting; Gregg Siegal; Iwan J P de Esch; Maarten H Vermeer; Cornelis P Tensen
Journal:  Oncotarget       Date:  2015-10-13

Review 10.  New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.

Authors:  Kazuyasu Fujii
Journal:  Front Oncol       Date:  2018-06-04       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.